Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

11.20USD
20 Apr 2018
Change (% chg)

$-0.36 (-3.11%)
Prev Close
$11.56
Open
$11.57
Day's High
$11.85
Day's Low
$11.19
Volume
75,787
Avg. Vol
81,847
52-wk High
$14.50
52-wk Low
$4.40

Chart for

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)

Overall

Beta: -0.10
Market Cap(Mil.): ¥50,795.66
Shares Outstanding(Mil.): 40.93
Dividend: --
Yield (%): --

Financials

  MNOV.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -34.24 -- --
ROI: -28.36 -0.74 13.19
ROE: -30.51 -2.80 15.00

BRIEF-MediciNova Announces Proposed Underwritten Public Offering

* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Feb 07 2018

BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)

* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

Dec 07 2017

BRIEF-Medicinova announces collaboration

* Medicinova announces collaboration with the U.S. Department Of Veterans Affairs and Oregon Health & Science University to evaluate MN-166 (ibudilast) in methamphetamine use disorder

Nov 09 2017

BRIEF-Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)

* Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability

Oct 26 2017

Earnings vs. Estimates